Clinical Value of rhBNP in the Treatment of Patients with Stanford Type B Aortic Dissection
PDF

Keywords

rhBNP
Stanford type B aortic dissection
Multi-organ protection

DOI

10.26689/jcnr.v6i3.3897

Abstract

Objective: To determine the clinical value of rhBNP in the treatment of patients with Stanford type B aortic dissection. Methods: From June 2018 to October 2021, 162 patients with Stanford type B aortic dissection were selected from the Cardiology Department of Henan Provincial Chest Hospital and randomly divided into two groups: control group (81 patients) and observation group (81 patients). The patients in the control group were treated with conventional therapy. On the basis of the control group, the patients in the observation group were treated with rhBNP. The cardiac function, renal function, pulmonary function, and inflammatory indices before and after treatment for 72 hours, as well as the incidence of adverse reactions between the two groups were compared. Results: After treatment, the cardiac function (LVEF and NT-pro BNP), renal function (urine output for 24 hours, Scr, and Cys-C), pulmonary function (PaO2, SPO2, and PaO2/FiO2), and inflammatory (IL-6, hsCRP, and MCP-1) indices of the observation group improved significantly compared to those of the control group (p < 0.05). Conclusion: rhBNP can improve cardiac function, renal function, and pulmonary function, as well as alleviate inflammation in patients with Stanford type B aortic dissection. Hence, in the treatment of patients with Stanford type B aortic dissection, rhBNP provides multi-organ protection.

References

Cao X, Xia HY, Zhang T, et al., 2015, Protective Effect of Lyophilized Recombinant Human Brain Natural Preference on Renal Ischemia/Rehabilitation Investment in Mice. Genet Mol Res, 14(4): 13300-13311.

Volpe M, 2014, Natriuretic Peptides and Cardio-Renal Disease. Int J Cardiol, 176(3): 630-639.

Zhang J, Fu X, Jia X, et a1., 2010, B-Type Natriuretic Peptide for Prevention of Contrast-Induced Nephropathy in Patients with Heart Failure Undergoing Primary Percutaneous Coronary Intervention. Acta Radiologica, 51(6): 641-648.

Lamia B, Maize J, Ochagavia A, et a1., 2009, Echocardiographic Diagnosis of Pulmonary Artery Occlusion Pressure Elevation During Weaning from Mechanical Ventilation. Crit Care Med, 37(5): 1696-1701.

Grasso S, Leone A, De Michele M, et al., 2007, Use of N-Terminal Pro-Brain Natriuretic Peptide to Detect Acute Cardiac Dysfunction During Weaning Failure in Difficult-to-Wean Patients with Chronic Obstructive Pulmonary Disease. Crit Care Med, 35(1): 96-105.

Vestbo J, Hurd SS, Agusti AC, et a1., 2013, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med, 187(4): 347-365.

Zapata L, Vera P, Roglan A, et a1., 2011, B-Type Natriuretic Peptides for Prediction and Diagnosis of Weaning Failure from Cardiac Origin. Intensive Care Med, 37(3): 477485.

Tanner H, Mohacsi P, Fuller-Bicer GA, et a1., 2007, Cytokine Activation and Disease Progression in Patients with Stable Moderate Chronic Heart Failure. J Heart Lung Transplant, 26(6): 622-629.

White M, Duchame A, Ibrahim R, et a1., 2006, Increased Systemic Inflammation and Oxidative Stress in Patients with Worsening Congestive Heart Failure: Improvement After Short-Term Inotropic Support. Clin Sci (Lond), 110(4): 483-489.